

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Single Technology Appraisal**


# Iptacopan for treating complement 3 glomerulopathy [ID6283]

#### Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Novartis (iptacopan)	All Wales Inherited Metabolic Disease
(4)	Service
Patient/carer groups	All Wales Therapeutics and Toxicology
Kidney Care UK	Centre
Kidney Research UK	Allied Health Professionals Federation
MPGN/DDD Support Group	Board of Community Health Councils in
National Kidney Federation	Wales
South Asian Health Foundation	British National Formulary
Specialised Healthcare Alliance	Care Quality Commission
, ,	Department of Health - Northern Ireland
Healthcare professional groups	Healthcare Improvement Scotland
Association of Renal Industries	Medicines and Healthcare products
Association of Renal Technologists	Regulatory Agency
British Association of Urological	National Association of Primary Care
Nurses	National Pharmacy Association
British Society for Immunology	NHS Confederation
Royal College of General Practitioners	Scottish Medicines Consortium
Royal College of Nursing	Welsh Government
Royal College of Pathologists	Welsh Health Specialised Services
Royal College of Physicians	Committee
Royal Pharmaceutical Society	
Royal Society of Medicine	Comparator companies
Society for DGH Nephrologists	Alexion Pharma (eculizumab)
UK Clinical Pharmacy Association	Amgen (eculizumab)
UK Kidney Association	Roche (mycophenolate mofetil)
UK Renal Pharmacy Group	Rosemont Pharmaceuticals
	(mycophenolate mofetil)
<u>Others</u>	Samsung Bioepis (eculizumab)
National Renal Complement	Teva Pharma (mycophenolate mofetil)
Therapeutics Centre	Tillomed Laboratories (mycophenolate
Department of Health and Social Care	mofetil)
NHS England	Polovant research groups
	Relevant research groups
	<ul><li>Cochrane Kidney and Transplant Group</li><li>Genomics England</li></ul>
	S .
	MRC Clinical Trials Unit

Final stakeholder list for the evaluation of iptacopan for treating complement 3 glomerulopathy [ID6283]

Issue date: January 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	<ul> <li>National Institute for Health Research</li> <li>Society for Research in Rehabilitation</li> <li>Wellcome Trust</li> </ul>
	<ul> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>
	<ul> <li>Evidence Review Group</li> <li>National Institute for Health Research Health Technology Assessment Programme (NETSCC)</li> </ul>
	<ul> <li>Associated Guideline Group</li> <li>NICE - National Guideline Alliance</li> <li>NICE - National Guideline Centre</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

### Consultees


Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of iptacopan for treating complement 3 glomerulopathy IID62831

Issue date: January 2025



#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.